CASI Pharmaceuticals Ownership
| CASI Stock | USD 1.38 0.04 2.99% |
Shares in Circulation | First Issued 1995-03-31 | Previous Quarter 15.5 M | Current Value 15.5 M | Avarage Shares Outstanding 4.5 M | Quarterly Volatility 6 M |
CASI Stock Ownership Analysis
About 58.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.89. CASI Pharmaceuticals had not issued any dividends in recent years. The entity had 1:10 split on the 2nd of June 2022. CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland. Casi Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 176 people. For more info on CASI Pharmaceuticals please contact RPh MBA at 86 10 6508 6063 or go to https://www.casipharmaceuticals.com.Besides selling stocks to institutional investors, CASI Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different CASI Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align CASI Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
CASI Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
About 58.0% of CASI Pharmaceuticals are currently held by insiders. Unlike CASI Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against CASI Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of CASI Pharmaceuticals' insider trades
CASI Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CASI Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CASI Pharmaceuticals backward and forwards among themselves. CASI Pharmaceuticals' institutional investor refers to the entity that pools money to purchase CASI Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Susquehanna International Group, Llp | 2025-06-30 | 10.2 K | Royal Bank Of Canada | 2025-06-30 | 9.9 K | Ubs Group Ag | 2025-06-30 | 954 | Wells Fargo & Co | 2025-06-30 | 505 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 365 | Blackrock Inc | 2025-06-30 | 296 | Bnp Paribas Arbitrage, Sa | 2025-06-30 | 134 | Simplex Trading, Llc | 2025-06-30 | 26.0 | Jpmorgan Chase & Co | 2025-06-30 | 25.0 | Vr Adviser, Llc | 2025-06-30 | 987.3 K | Foresite Capital Management Vi Llc | 2025-06-30 | 787.1 K |
CASI Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CASI Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on CASI Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CASI Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Wealth Strategy Holding Ltd over a month ago Disposition of 370370 shares by Wealth Strategy Holding Ltd of CASI Pharmaceuticals at 3.69 subject to Rule 16b-3 | ||
Wealth Strategy Holding Ltd over two months ago Disposition of 493827 shares by Wealth Strategy Holding Ltd of CASI Pharmaceuticals at 1.69 subject to Rule 16b-3 | ||
He Wei-wu over six months ago Acquisition by He Wei-wu of 234488 shares of CASI Pharmaceuticals at 1.57 subject to Rule 16b-3 | ||
Wu Yue Alexander over six months ago Acquisition by Wu Yue Alexander of 110459 shares of CASI Pharmaceuticals at 1.65 subject to Rule 16b-3 | ||
Wu Yue Alexander over a year ago Acquisition by Wu Yue Alexander of 388387 shares of CASI Pharmaceuticals at 0.4664 subject to Rule 16b-3 | ||
Salisbury Franklin Cary Jr over a year ago Acquisition by Salisbury Franklin Cary Jr of 388387 shares of CASI Pharmaceuticals subject to Rule 16b-3 |
CASI Pharmaceuticals Outstanding Bonds
CASI Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CASI Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CASI bonds can be classified according to their maturity, which is the date when CASI Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Currently Active Assets on Macroaxis
When determining whether CASI Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CASI Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Casi Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Casi Pharmaceuticals Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CASI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CASI Pharmaceuticals. If investors know CASI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.89) | Revenue Per Share | Quarterly Revenue Growth 0.049 | Return On Assets | Return On Equity |
The market value of CASI Pharmaceuticals is measured differently than its book value, which is the value of CASI that is recorded on the company's balance sheet. Investors also form their own opinion of CASI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is CASI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CASI Pharmaceuticals' market value can be influenced by many factors that don't directly affect CASI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CASI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if CASI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CASI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.